ERBB2 and breast carcinoma: For example, trastuzumab, approved in 1998, in combination with chemotherapy for human epidermal growth factor receptor 2 positive (HER2+) for early breast cancer; pertuzumab, approved in 2012, in combination with trastuzumab is indicated for metastatic breast cancer in HER2+; or panitumumab, approved in 2006, for first-line metastatic RAS/wild-type colorectal cancer in combination with FOLFIRI, for approximately 40% of patients.